PatrickM.ReaganMD

PubMed

• Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
  Jonathan W Friedberg, Michael T Brady, Myla Strawderman, Brad S Kahl, Izidore S Lossos
  Eclinicalmedicine. 2024-12-01
• 1 citations
  Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
  Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq
  Blood Advances. 2024-08-27
• 3 citations
  Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
  Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David B Miklos
  Blood Advances. 2024-06-11

Abstracts/Posters

• PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018